Status:
COMPLETED
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
Lead Sponsor:
Region Skane
Conditions:
RA
SLE
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on immune response elicited by pneumococcal ...
Eligibility Criteria
Inclusion
- Adult patients with IRD receiving active anti-rheumatic treatments with DMARDs or biological remedies are offered to participate in the study. The protocol permits stratification for prednisolone usage, smoking habits and alcohol consumption.
Exclusion
- age \<18 years;
- pregnancy,
- known intolerance of vaccine,
- ongoing infection
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT02240888
Start Date
October 1 2011
End Date
May 31 2018
Last Update
October 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skåne University hospital, Dept of rheumatology
Lund, Sweden, SE-22185